Replacement Therapy with the Surfactant Alveofact for Neonatal Respiratory Distress Syndrome: A Pilot Study
https://doi.org/10.15360/1813-9779-2014-4-44-50
Abstract
Objective: to evaluate the efficacy of alveofact in neonatal infants with respiratory distress syndrome (RDS).
Subjects and methods. The trial enrolled 5 premature neonatal infants. Their mean gestational age was 30.2±2.3 weeks; the birth weight was 1422±604 g. All the premature neonates needed mechanical ventilation (MV) because the leading clinical sign was severe respiratory failure. The surfactant alveofact was injected endotracheally in all the neonates at 3—5 minutes of life, by taking into account their gestational age and birth MV. The mean dose of the agent was 50 mg/kg).
Results. The pilot study indicated the efficacy of alveofact. There was normalization of lung gasexchange function parameters after alveofact
injection within the first 24 hours of life. Alveofact administration allows MV with the parameters close to physiological ones.
About the Author
S. A. PerepelitsaRussian Federation
References
1. Perepelitsa S.A., Golubev A.M., Moroz V.V., Alekseyeva S.V., Melnichenko V.A. Vospalitelnye izmeneniya v platsente i bakterialnaya infektsiya u nedonoshennykh novorozhdennykh s dykhatelnoi nedostatochnostyu. Obshchaya Reanimatologiya. [Placental inflamma tory changes and bacterial infection in premature neonates with respi ratory failure. General Reanimatology]. 2012; 8 (3): 18—24. [In Russ.]
2. Perepelitsa S.A., Golubev A.M., Moroz V.V. Respiratornyi distresssin drom novorozhdennykh: rannyaya diagnostika, profilaktika i lechenie. Obshchaya Reanimatologiya. [Neonatal respiratory distress syndrome: early diagnosis, preventation, and treatment. General Reanimatology]. 2012; 8 (4): 95—102. [In Russ.]
3. Perepelitsa S.A., Golubev A.M., Moroz V.V., Alekseyeva S.V. Prichiny ostroi intranatalnoi i postnatalnoi gipoksii u novorozhdennykh.
4. Obshchaya Reanimatologiya. [Causes of acute intranatal and postna tal hypoxia in neonatal infants. General Reanimatology]. 2012; 8 (6): 17—22. [In Russ.]
5. Perestoronina M.V., Korpacheva O.V., Palyanov S.V., Nikolaev S.V. Problemy otsenki kislorodnogo statusa u novorozhdennykh s ekstremalno nizkoi massoi tela. Obshchaya Reanimatologiya. [Problems in the evaluation of oxygen status in extremely low birth weight neonates. General Reanimatology]. 2012; 8 (5): 77—81. [In Russ.]
6. Perepelitsa S.A., Alekseyeva S.V., Sergunova V.A., Gudkova O.E. Nanostruktura membran eritrotsitov nedonoshennykh novorozhdennykh s respiratornym distresssindromom. Obshchaya Reanimatologiya. [Nanostructure of red blood cell membranes in premature neonates with respiratory distress syndrome. General Reanimatology]. 2013; 9 (6): 11—23. [In Russ.]
7. Volodin N.N. (ed.). Vedenie novorozhdennykh s respiratornym distress sindromom. Metodicheskie rekomendatsii. [Management of neonatal respiratory distress syndrome. Guidelines]. Moscow; 2014: 72. [In Russ.]
8. Rosenberg O.A. Legochnyi surfaktant i ego primenenie pri zabolevanii legkikh. Obshchaya Reanimatologiya. [Lung surfactant and its use in lung diseases. General Reanimatology ]. 2007; 3 (1): 66–77. [In Russ.]
9. Moroz V.V., Golubev A.M., Perepelitsa S.A. Respiratornyi distresssin drom novorozhdennykh. Patogenez, diagnostika, klinika, lechenie. [Neonatal respiratory distress syndrome: Pathogenesis, diagnosis, clin ical presentation, treatment]. Saarbrьcken: Palmarium Academic Publishing; 2014: 127. [In Russ.]
10. Alveofakt. Naturalnyi surfactant. [Alveofact. A natural surfactant]. LyomarkPharma; 2012: 96. [In Russ.]
11. Vinogradova I.V., Nikiforova G.I. Primenenie surfaktanta BL u novorozhdennykh s sindromom aspiratsii mekoniya. [Use of the sur factant BL in neonatal infants with meconium aspiration syndrome]. Rossiisky Vestnik Perinatologii i Pediatrii 2011; 4: 15—19. [In Russ.]
12. Volodin N.N., Degtyarev D.N., Babak O.A., Levadnaya A.V. Ispolzovanie ekzogennogo surfaktanta u nedonoshennykh detei pri bronkholegochnoi displazii. [Use of exogenous surfactant in premature infants with bron chopulmonary dysplasia]. Vestnik Rossiiskogo Gosudarstvennogo Meditsinskogo Universiteta. 2010; 2: 41—46. [In Russ.]
13. Singh N., Hawley K.L., Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syn drome: systematic review and metaanalysis. Pediatrics. 2011; 128 (6): e1588–e1595. http://dx.doi.org/10.1542/peds.20111395. PMID: 22123870
14. Sweet D.G., Carnielli V., Greisen G., Hallman M., Ozek E., Plavka R., Saugstad O.D., Simeoni U., Speer C.P., Vento M., Halliday H.L.; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syn drome in preterm infants – 2013 update. Neonatology. 2013; 103 (4): 353–368. http://dx.doi.org/10.1159/000349928. PMID: 23736015
15. Gortner L., Wauer R.R., Hammer H., Stock G.J., Heitmann F., Reiter H.L., Kühl P.G., Möller J.C., Friedrich H.J., Reiss I., Hentschel R., Jorch G., Hieronimi G., Kuhls E. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks’ gestational age: a multicenter controlled clinical trial. Pediatrics. 1998; 102 (5): 1153—1160. http://dx.doi.org/10. 1542/peds.102.5.1153. PMID: 9794948
16. Proquitte H., Dushe T., Hammer H., Rüdiger M., Schmalisch G., Wauer R. R. Observational study to compare the clinical efficacy of the natural surfac tants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. Respir. Med. 2007; 101 (1): 169–176. http://dx.doi.org/10.1016/j.rmed.2006.03.033. PMID: 16698258
17. Polin R.A., Carlo W.A.; Committee on Fetus and Newborn; American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014; 133 (1): 156—163. http://dx.doi.org/10.1542/peds.20133443. PMID: 24379227
Review
For citations:
Perepelitsa S.A. Replacement Therapy with the Surfactant Alveofact for Neonatal Respiratory Distress Syndrome: A Pilot Study. General Reanimatology. 2014;10(4):44-50. https://doi.org/10.15360/1813-9779-2014-4-44-50